Industry Growth Insights published a new data on “Duchenne Muscular Dystrophy Drugs Market”. The research report is titled “Duchenne Muscular Dystrophy Drugs Market research by Types (Development & Drug Target, Mechanism of Action (MoA), Route of Administration (RoA), Molecule Type), By Applications (Hospitals and Clinics, Medical Laboratories, Others), By Players/Companies Akashi Therapeutics Inc, Antisense Therapeutics Ltd, Beech Tree Labs Inc, Biogen Inc, Bioleaders Corp, BioMarin Pharmaceutical Inc, Biophytis SAS, Capricor Therapeutics Inc, Catabasis Pharmaceuticals Inc, CRISPR Therapeutics, Cumberland Pharmaceuticals Inc, Daiichi Sankyo Co Ltd, Debiopharm International SA, Editas Medicine Inc, Eloxx Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, FibroGen Inc, Fulcrum Therapeutics Inc, Galapagos NV, Genethon SA, GTx Inc, Santhera Pharmaceuticals Holding AG, Sarepta Therapeutics Inc, SOM Biotech SL, Strykagen Corp, Summit Therapeutics Plc, Taiho Pharmaceutical Co Ltd, Teijin Pharma Ltd, WAVE Life Sciences Ltd”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Duchenne Muscular Dystrophy Drugs Market Research Report
By Type
Development & Drug Target, Mechanism of Action (MoA), Route of Administration (RoA), Molecule Type
By Application
Hospitals and Clinics, Medical Laboratories, Others
By Companies
Akashi Therapeutics Inc, Antisense Therapeutics Ltd, Beech Tree Labs Inc, Biogen Inc, Bioleaders Corp, BioMarin Pharmaceutical Inc, Biophytis SAS, Capricor Therapeutics Inc, Catabasis Pharmaceuticals Inc, CRISPR Therapeutics, Cumberland Pharmaceuticals Inc, Daiichi Sankyo Co Ltd, Debiopharm International SA, Editas Medicine Inc, Eloxx Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, FibroGen Inc, Fulcrum Therapeutics Inc, Galapagos NV, Genethon SA, GTx Inc, Santhera Pharmaceuticals Holding AG, Sarepta Therapeutics Inc, SOM Biotech SL, Strykagen Corp, Summit Therapeutics Plc, Taiho Pharmaceutical Co Ltd, Teijin Pharma Ltd, WAVE Life Sciences Ltd
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Duchenne Muscular Dystrophy Drugs Market Report Segments:
The global Duchenne Muscular Dystrophy Drugs market is segmented on the basis of:
Types
Development & Drug Target, Mechanism of Action (MoA), Route of Administration (RoA), Molecule Type
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals and Clinics, Medical Laboratories, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Akashi Therapeutics Inc
- Antisense Therapeutics Ltd
- Beech Tree Labs Inc
- Biogen Inc
- Bioleaders Corp
- BioMarin Pharmaceutical Inc
- Biophytis SAS
- Capricor Therapeutics Inc
- Catabasis Pharmaceuticals Inc
- CRISPR Therapeutics
- Cumberland Pharmaceuticals Inc
- Daiichi Sankyo Co Ltd
- Debiopharm International SA
- Editas Medicine Inc
- Eloxx Pharmaceuticals Inc
- F. Hoffmann-La Roche Ltd
- FibroGen Inc
- Fulcrum Therapeutics Inc
- Galapagos NV
- Genethon SA
- GTx Inc
- Santhera Pharmaceuticals Holding AG
- Sarepta Therapeutics Inc
- SOM Biotech SL
- Strykagen Corp
- Summit Therapeutics Plc
- Taiho Pharmaceutical Co Ltd
- Teijin Pharma Ltd
- WAVE Life Sciences Ltd
Highlights of The Duchenne Muscular Dystrophy Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Development & Drug Target
- Mechanism of Action (MoA)
- Route of Administration (RoA)
- Molecule Type
- By Application:
- Hospitals and Clinics
- Medical Laboratories
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Duchenne Muscular Dystrophy Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Duchenne Muscular Dystrophy (DMD) is a rare genetic muscle-wasting disorder. There are currently no FDA-approved drugs specifically for DMD, but there are many treatments that can help improve the quality of life for people with the disorder. Some common treatments include physical therapy, speech therapy, and occupational therapy. Many families also choose to use supplements or medications to help improve muscle strength and function.
Some of the key players operating in the duchenne muscular dystrophy drugs market are Akashi Therapeutics Inc, Antisense Therapeutics Ltd, Beech Tree Labs Inc, Biogen Inc, Bioleaders Corp, BioMarin Pharmaceutical Inc, Biophytis SAS, Capricor Therapeutics Inc, Catabasis Pharmaceuticals Inc, CRISPR Therapeutics, Cumberland Pharmaceuticals Inc, Daiichi Sankyo Co Ltd, Debiopharm International SA, Editas Medicine Inc, Eloxx Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, FibroGen Inc, Fulcrum Therapeutics Inc, Galapagos NV, Genethon SA, GTx Inc, Santhera Pharmaceuticals Holding AG, Sarepta Therapeutics Inc, SOM Biotech SL, Strykagen Corp, Summit Therapeutics Plc, Taiho Pharmaceutical Co Ltd, Teijin Pharma Ltd, WAVE Life Sciences Ltd.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Duchenne Muscular Dystrophy Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Duchenne Muscular Dystrophy Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Duchenne Muscular Dystrophy Drugs Market - Supply Chain
4.5. Global Duchenne Muscular Dystrophy Drugs Market Forecast
4.5.1. Duchenne Muscular Dystrophy Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Duchenne Muscular Dystrophy Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Duchenne Muscular Dystrophy Drugs Market Absolute $ Opportunity
5. Global Duchenne Muscular Dystrophy Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Duchenne Muscular Dystrophy Drugs Market Size and Volume Forecast by Type
5.3.1. Development & Drug Target
5.3.2. Mechanism of Action (MoA)
5.3.3. Route of Administration (RoA)
5.3.4. Molecule Type
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Duchenne Muscular Dystrophy Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Duchenne Muscular Dystrophy Drugs Market Size and Volume Forecast by Application
6.3.1. Hospitals and Clinics
6.3.2. Medical Laboratories
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Duchenne Muscular Dystrophy Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Duchenne Muscular Dystrophy Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Duchenne Muscular Dystrophy Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Duchenne Muscular Dystrophy Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Duchenne Muscular Dystrophy Drugs Demand Share Forecast, 2019-2026
9. North America Duchenne Muscular Dystrophy Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Duchenne Muscular Dystrophy Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Duchenne Muscular Dystrophy Drugs Market Size and Volume Forecast by Application
9.4.1. Hospitals and Clinics
9.4.2. Medical Laboratories
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Duchenne Muscular Dystrophy Drugs Market Size and Volume Forecast by Type
9.7.1. Development & Drug Target
9.7.2. Mechanism of Action (MoA)
9.7.3. Route of Administration (RoA)
9.7.4. Molecule Type
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Duchenne Muscular Dystrophy Drugs Demand Share Forecast, 2019-2026
10. Latin America Duchenne Muscular Dystrophy Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Duchenne Muscular Dystrophy Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Duchenne Muscular Dystrophy Drugs Market Size and Volume Forecast by Application
10.4.1. Hospitals and Clinics
10.4.2. Medical Laboratories
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Duchenne Muscular Dystrophy Drugs Market Size and Volume Forecast by Type
10.7.1. Development & Drug Target
10.7.2. Mechanism of Action (MoA)
10.7.3. Route of Administration (RoA)
10.7.4. Molecule Type
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Duchenne Muscular Dystrophy Drugs Demand Share Forecast, 2019-2026
11. Europe Duchenne Muscular Dystrophy Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Duchenne Muscular Dystrophy Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Duchenne Muscular Dystrophy Drugs Market Size and Volume Forecast by Application
11.4.1. Hospitals and Clinics
11.4.2. Medical Laboratories
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Duchenne Muscular Dystrophy Drugs Market Size and Volume Forecast by Type
11.7.1. Development & Drug Target
11.7.2. Mechanism of Action (MoA)
11.7.3. Route of Administration (RoA)
11.7.4. Moleule Type
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Duchenne Muscular Dystrophy Drugs Demand Share, 2019-2026
12. Asia Pacific Duchenne Muscular Dystrophy Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Duchenne Muscular Dystrophy Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Duchenne Muscular Dystrophy Drugs Market Size and Volume Forecast by Application
12.4.1. Hospitals and Clinics
12.4.2. Medical Laboratories
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Duchenne Muscular Dystrophy Drugs Market Size and Volume Forecast by Type
12.7.1. Development & Drug Target
12.7.2. Mechanism of Action (MoA)
12.7.3. Route of Administration (RoA)
12.7.4. Molecule Type
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Duchenne Muscular Dystrophy Drugs Demand Share, 2019-2026
13. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size and Volume Forecast by Application
13.4.1. Hospitals and Clinics
13.4.2. Medical Laboratories
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size and Volume Forecast by Type
13.7.1. Development & Drug Target
13.7.2. Mechanism of Action (MoA)
13.7.3. Route of Administration (RoA)
13.7.4. Molecule Type
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Duchenne Muscular Dystrophy Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Duchenne Muscular Dystrophy Drugs Market: Market Share Analysis
14.2. Duchenne Muscular Dystrophy Drugs Distributors and Customers
14.3. Duchenne Muscular Dystrophy Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Akashi Therapeutics Inc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Antisense Therapeutics Ltd
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Beech Tree Labs Inc
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Biogen Inc
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Bioleaders Corp
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. BioMarin Pharmaceutical Inc
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Biophytis SAS
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Capricor Therapeutics Inc
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Catabasis Pharmaceuticals Inc
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. CRISPR Therapeutics
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Cumberland Pharmaceuticals Inc
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Daiichi Sankyo Co Ltd
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Debiopharm International SA
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Editas Medicine Inc
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Eloxx Pharmaceuticals Inc
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. F. Hoffmann-La Roche Ltd
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. FibroGen Inc
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Fulcrum Therapeutics Inc
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. Galapagos NV
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. Genethon SA
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook